NetworkNewsBreaks – Why Silo Pharma Inc. (SILO) Is ‘One to Watch’
Silo Pharma (OTCQB: SILO) is committed to developing innovative solutions to address various underserved conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders as part of its focus on merging traditional therapeutics with psychedelic research. “Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves,” a recent article reads. Silo Pharma is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease; a scientific research agreement with the University of California San Francisco (“UCSF”) leveraging four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation; an exclusive option agreement with the University of Maryland, Baltimore to explore a novel invention generally known as joint-homing peptide and its use in arthritis-inflamed joints; and an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation as well as a prophylactic treatment for stress-induced disorders and PTSD. “In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (‘ZTI’), focused on the development of ketamine and psilocybin using ZTI’s Z-Pod(TM) technology for the transdermal time-released delivery of therapeutics.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Silo Pharma (OTCQB: SILO) is committed to developing innovative solutions to address various underserved conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders as part of its focus on merging traditional therapeutics with psychedelic research. “Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves,” a recent article reads. Silo Pharma is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease; a scientific research agreement with the University of California San Francisco (“UCSF”) leveraging four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation; an exclusive option agreement with the University of Maryland, Baltimore to explore a novel invention generally known as joint-homing peptide and its use in arthritis-inflamed joints; and an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation as well as a prophylactic treatment for stress-induced disorders and PTSD. “In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (‘ZTI’), focused on the development of ketamine and psilocybin using ZTI’s Z-Pod(TM) technology for the transdermal time-released delivery of therapeutics.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
